Wu Yu'e, Liu Yujie, Jia Huanhuan, Luo Chao, Chen Huan
Guangdong Laboratory Animals Monitoring Insitute, Guangdong Provincial Key Laboratory of Laboratory Animals, Guangzhou, China.
Department of Obstetrics, Zhuzhou Central Hospital, Zhuzhou, China.
Front Surg. 2022 Nov 1;9:992490. doi: 10.3389/fsurg.2022.992490. eCollection 2022.
Endometriosis is now considered to be a systemic disease rather than a disease that primarily affects the pelvis. Dienogest (DNG) has unique advantages in the treatment of endometriosis, but it also has side effects. Alternatively, Traditional Chinese Medicine (TCM) has been used for over 2000 years in the treatment and prevention of disease and growing numbers of Chinese scholars are experimenting with the combined use of Dienogest and TCM for endometriosis treatment.
This review evaluated the efficacy and safety of TCM in combination with Dienogest in the treatment of endometriosis through meta-analysis.
MEDLINE, Embase, the Cochrane Library, PubMed, Web of Science, China National Knowledge Infrastructure, Journal Integration Platform, and Wanfang were used in literature searches, with a deadline of May 31, 2022. Literature quality was assessed using the Cochrane Collaboration "risk of bias" (ROB2) tool, and the "meta" package of R software v.4.1 was used for meta-analysis. Dichotomous variables and continuous variables were assessed using the relative risk (RR) and 95% confidence intervals (95% CI); standard mean differences (MD) and 95% CI, respectively.
Twelve human randomized controlled trials (RCTs) and one retrospective study, all 13 written in the Chinese language, were included in the meta-analysis (720 experiments and 719 controls). The result indicated that TCM plus Dienogest was superior to Dienogest/TCM alone in increasing the cure rates (RR = 1.3780; 95% CI, 1.1058, 1.7172; = 0.0043), remarkable effect rate (RR = 1.3389; 95% CI, 1.1829, 1.5154; < 0.0001), invalid rate (RR = 0.2299; 95% CI, 0.1591, 0.3322; < 0.0001), and rate of adverse effects (RR = 0.6177; 95% CI, 0.4288, 0.8899; = 0.0097). The same conclusion was drawn from the subgroup analysis.
Results suggest that TCM combined with Dienogest is superior to Dienogest or TCM alone and can be used as a complementary treatment for endometriosis. TCMs have potential to improve clinical efficacy and reduce the side effects of Dienogest. This study was financially supported by Annual Science and Technology Steering Plan Project of Zhuzhou. PROSPERO has registered our meta-analysis as CRD42022339518 (https://www.crd.york.ac.uk/prospero/record_email.php).
子宫内膜异位症现在被认为是一种全身性疾病,而非主要影响盆腔的疾病。地诺孕素(DNG)在子宫内膜异位症的治疗中具有独特优势,但也有副作用。另外,中医在疾病的治疗和预防方面已有两千多年的应用历史,越来越多的中国学者正在尝试将地诺孕素与中医结合用于子宫内膜异位症的治疗。
本综述通过荟萃分析评估中医联合地诺孕素治疗子宫内膜异位症的疗效和安全性。
检索了MEDLINE、Embase、Cochrane图书馆、PubMed、Web of Science、中国知网、期刊集成平台和万方数据库,检索截止日期为2022年5月31日。使用Cochrane协作网的“偏倚风险”(ROB2)工具评估文献质量,并使用R软件v.4.1的“meta”包进行荟萃分析。二分类变量和连续变量分别使用相对风险(RR)和95%置信区间(95%CI)、标准化均数差(MD)和95%CI进行评估。
荟萃分析纳入了12项人类随机对照试验(RCT)和1项回顾性研究,所有13篇文献均为中文(720例试验组和719例对照组)。结果表明,中医联合地诺孕素在提高治愈率(RR = 1.3780;95%CI,1.1058,1.7172;P = 0.0043)、显效率(RR = 1.3389;95%CI,1.1829,1.5154;P < 0.0001)、无效率(RR = 0.2299;95%CI,0.1591,0.3322;P < 0.0001)和不良反应发生率(RR = 0.6177;95%CI,0.4288,0.8899;P = 0.0097)方面优于单独使用地诺孕素/中医。亚组分析得出了相同的结论。
结果表明,中医联合地诺孕素优于单独使用地诺孕素或中医,可作为子宫内膜异位症的辅助治疗方法。中药有提高临床疗效和降低地诺孕素副作用的潜力。本研究得到株洲市年度科技导向计划项目的资助。PROSPERO已将我们的荟萃分析注册为CRD42022339518(https://www.crd.york.ac.uk/prospero/record_email.php)。